Differences in both matrix metalloproteinase 9 concentration and zymographic profile between plasma and serum with clot activators are due to the presence of amorphous silica or silicate salts in blood collection devices.

Author(s): Mannello F, Tanus-Santos JE, Meschiari CA, Tonti GA

Publication: Anal Biochem, 2008, Vol. 374, Page 56-63

PubMed ID: 18082127 PubMed Review Paper? No

Purpose of Paper

Conclusion of Paper

Studies

1. Study Purpose

   The purpose of this study was to determine the effects of collection container and added silica on MMP-2 and MMP-9 levels in serum and plasma specimens.

   Summary of Findings:

   Collection tube type and treatment with silica did not affect levels of MMP-2. Levels of MMP-9 decreased with silica treatment prior to separation of the plasma and serum, but were unaffected by addition of silica or silicate to separated plasma or serum. Plasma levels of MMP-9 were higher than levels in serum collected with clot activators. Serum collected in plastic tubes had less MMP-9 than serum collected in glass tubes.

   Biospecimens

   • Bodily Fluid - Plasma
   • Bodily Fluid - Serum
   • Bodily Fluid - Blood

   Preservative Types

   • None (Fresh)

   Diagnoses:

   • Normal

   Platform:

   Analyte	Technology Platform
   Protein	ELISA
   Protein	Zymography

   Pre-analytical Factors:

   Classification	Pre-analytical Factor	Value(s)
   Biospecimen Aliquots and Components	Blood and blood products	Plasma Serum
   Biospecimen Aliquots and Components	Biospecimen mixing	Added Silica prior to blood collection Silica added after separation
   Biospecimen Acquisition	Type of collection container/solution	Plastic Glass Plastic with sprayed nonsoluble silica Plastic tube with silica gel-coated surface Natrium citrate plasma tube

   View more